This transcript has been edited for clarity.
Hi. This is Jay Shubrook, family physician and diabetologist at Touro University. I am here at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California.
What are the three things that I think are the major takeaways from these sessions for primary care?
Type 2 diabetes in younger patients. We have some bad news. We know that type 2 diabetes is increasingly common in children and young adults, and that this disease is more virulent and progresses more quickly in those younger people. So look at the results of the Longitudinal Outcomes in Youth With Type 2 Diabetes (TODAY-2) trial.
(Editor's note: The results of the Restoring Insulin Secretion (RISE) trial in adolescents were also presented at ADA and provided sobering data on morbidity of type 2 diabetes in adolescents and young adults, described by one expert as "like watching a car crash in slow motion.")
Renal benefit from some antidiabetic agents. Second, we know that this is the year of the kidney. We have many studies that were presented here, including the REWIND and CREDENCEdata, which showed that people with type 2 diabetes and kidney disease receive a substantial benefit from GLP-1 receptor agonists and SGLT2 inhibitors.
Reducing Albumin Improves Kidney and Heart Function in People With Type 2 Diabetes
Biosimilars May Finally Stop the Rocketing Cost of Insulin
Atherosclerosis and Diabetes Synergistic, Deadlier in South Asians
Type 2 Diabetes Mellitus
Pediatric Type 2 Diabetes Mellitus
Skill Checkup: An 80-Year-Old Man With a History of HFrEF, AF, and T2D Is Experiencing Acute Shortness of Breath
COMMENTARY
Type 2 Diabetes: Three New Messages for Primary Care From ADA 2019
Jay H. Shubrook, DO
DisclosuresJuly 08, 2019
This transcript has been edited for clarity.
Hi. This is Jay Shubrook, family physician and diabetologist at Touro University. I am here at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California.
What are the three things that I think are the major takeaways from these sessions for primary care?
Type 2 diabetes in younger patients. We have some bad news. We know that type 2 diabetes is increasingly common in children and young adults, and that this disease is more virulent and progresses more quickly in those younger people. So look at the results of the Longitudinal Outcomes in Youth With Type 2 Diabetes (TODAY-2) trial.
(Editor's note: The results of the Restoring Insulin Secretion (RISE) trial in adolescents were also presented at ADA and provided sobering data on morbidity of type 2 diabetes in adolescents and young adults, described by one expert as "like watching a car crash in slow motion.")
Renal benefit from some antidiabetic agents. Second, we know that this is the year of the kidney. We have many studies that were presented here, including the REWIND and CREDENCEdata, which showed that people with type 2 diabetes and kidney disease receive a substantial benefit from GLP-1 receptor agonists and SGLT2 inhibitors.
Medscape Family Medicine © 2019 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Type 2 Diabetes: Three New Messages for Primary Care From ADA 2019 - Medscape - Jul 08, 2019.
Tables
Authors and Disclosures
Authors and Disclosures
Author
Jay H. Shubrook, DO
Professor, Primary Care Department; Director, Clinical Research and Diabetes Services, College of Osteopathic Medicine, Touro University California, Vallejo, California
Disclosure: Jay H. Shubrook, DO, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Eli Lilly; Novo Nordisk; Intarcia, Sanofi